The efficacy and safety of cilnidipine on mild to moderate essential hypertension: A systematic review and meta-analysis of randomized controlled trials in Chinese patients

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 12, Issue 1, 2012, Pages 56-62

  Xu, Guoliang ^a   Wu, Haidi ^a   Du, Bing ^a   Qin, Ling ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

Cilnidipine; Essential hypertension; Meta analysis; Systematic review

Indexed keywords

AMLODIPINE; CILNIDIPINE;

BLOOD PRESSURE REGULATION; CHINESE; COUGHING; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; ESSENTIAL HYPERTENSION; GASTROINTESTINAL SYMPTOM; HEADACHE; HOT FLUSH; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TABLET;

CALCIUM CHANNEL BLOCKERS; CHINA; DIHYDROPYRIDINES; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84867487658     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152912801823165     Document Type: Review

References (25)

1. Papadopoulos D.P.; Papademetriou V. Low-dose fixed combination of bisoprolol/ hydrochlorothiazide as first line for hypertension: a review of the rationale and clinical evidence. Angiology, 2009, 60(5), 601-607.
2. Liu L.S.; Wang W.; Yao C.H. Hypertension prevention guide (2009 grass-roots version). Chin. J. Hypertension, 2010, 18 (1), 11-30.
3. Law M.R.; Morris J.K.; Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ, 2009, 338, 1665.
4. Zhang H.; Zhao X.L. New calcium channel blocker-cilnidipine. Evaluation and analysis of drug use in hospitals of China, 2003, 3(2), 126-128.
5. Sackett D.L.; Clarke M.; Oxman A.D. (2002). Cochrane Reviewers, Handbook 4.2, In Renew Manager. Versions 4.2.Oxford, England:The cochrane collaboration, 2002, 13-36.
6. WHO-ISH Hypertension Guidelines Committee. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J. Hypertens, 1999, 17(2), 15l-183.
7. Committee of guidebook on prevention and treatment of hypertension. Guidebook on prevention and treatment of hypertension. Chinese J. Hyperten., 2000, 8(2), 103-112.
8. Liu G.Z.; Hu D.Y.; Tao P.; Chu J.R.; Guo L.N.; Guo J.X.; You K. Recommendations on evaluation of clinical trials of cardiovascular drugs. Chin. J. Cardiol., 1998, 26(1), 7-9.
9. Jadad A.R.; Moore A.; Carroll D.; Jenkinson C.; Reynolds D.J.; Gavaghan D.J.; McQuay H.J. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin.Trials, 1996, 17(1), 1-12.
10. Moher D.; Cook DJ.; Eastwood S.; Olkin I.; Rennie D.; Stroup D.F. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet, 1999, 354(9193), 1896-1900.
11. Zhang X.Y.; Liu G.S. The comparition of efficacy and safety on treatment of essential hypertension between domestic cilnidipine and Amlodipine. Med. J. Chin. PLA, 2003, 28(9): 851.
12. Chen Y.Y; Sun N.L.; Zhao X.L.; Jia S.Q.; Guo Y.Z.; Wang L.; Yao C.; Lu X.N. The efficacy and safety study of domestic cilnidipine treatment of mild to moderate hypertension. Chin. J. Clin. Pharmacol., 2003, 19(5), 334-337.
13. Liang Y.Z.; Wang L.; Huang T.G.; Yin L.; Zhou L.J. The clinical observation of cilnidipine treatment of mild to moderate hypertension. Tianjin Med. J., 2003, 31(6), 365-367.
14. Ma S.P.; Guo X.M.; Li C.R.; Wu D. The efficacy and safety of cilnidipine treatment of mild to moderate hypertension. Chin J. New Drugs Clin. Rem., 2004, 23(12), 873-875.
15. Chen J.T.; Sun N.L.; Chen Y.Y.; Guo D.J.; Wu Y. The comparition of efficacy and safety on treatment of essential hypertension between cilnidipine and amlodipine. Clin. Med. China, 2004, 20(3), 197-199.
16. Zhao X.L.; Zhang H.; Hu D.Y. The efficacy and safety of cilnidipine treatment of mild to moderate hypertension. Chin J. Clin. Pharmacol., 2005, 21(1), 8-10.
17. Jing S.; Sun N.L.; Wang H.P.; Lu X.N. The efficacy and safety of Domestic cilnidipine treatment of mild to moderate hypertension. Chin. J. New Drugs, 2005, 14(4), 473-475.
18. Huang L.L.; Li G.Y.; Bai Y. Cilnidipine treatment of mild to moderate essential hypertension in 25 cases. Herald of Medicine, 2006, 25(9), 919-920.
19. Huang G.Z.; Wu Z.G.; Lu G.P.; Zheng X.; Huang Z.Y.; Wang H.; Sun C.B.; Gao Y.; Tang Y.H. Domestic cilnidipine treatment of mild to moderate essential hypertension. Chin. J. Hyperten., 2007, 15(2), 124-127.
20. Zhao X.L.; Zhou Y.M.; Li J.; Xiao J.; Wang J.Q.; Zhou H. The efficacy and safety of cilnidipine treatment of mild to moderate hypertension. Chinese Journal of New Drugs, 2008, 17(2), 157-159.
21. Zhou X.L. The efficient observation of cilnidipine treatment of mild to moderate hypertension. Chin. J. Clin. Rat. Drug Use, 2011, 4(1A), 49-50.
22. Wang J.Y.; Miu E.Y.; Hang C.X.; Hua Q. Internal Medicine. Beijing: People's Medical Publishing House, 2010, 266-267.
23. ++ channel in rat dorsal root ganglion neurons. J. Pharmacol. Exp. Ther., 1997, 280(3), 1184-1191.
24. Hosono M.; Fujii S.; Hiruma T.; Watanabe K.; Hayashi Y.; Ohnishi H.; Takata Y.; Kato H. Inhibitory effect of cilnidipine on vascular sympathetic neurotransmission and subsequent vasoconstriction in spontaneously hypertensive rats. Jpn. J. Pharmacol, 1995, 69(2), 127-134.
25. Jasmina J.; Dinko S.; Edward F. Cilnidipine improves spontaneously hypertensive rat coronary hemodynamics without altering cardiovascular mass and collagen. J. Hypertens, 2002, 20(2), 317-322.